← Leaderboards
Tetsuo Ashizawa
Methodist Hospital Research Institute
$6,798,395
Attributed
$11,986,352
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–23$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,986,352 · 6
By mechanism
U01$6,148,541 · 1
R01$4,817,811 · 3
RC1$1,000,000 · 1
R13$20,000 · 1
Top collaborators
- Gulin Oz6 shared
- Alexandra Durr5 shared
- Thomas Klockgether5 shared
- Henry L Paulson5 shared
- Laura B Jardim4 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Laura B Jardim$318,264
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationSpinocerebellar AtaxiasGeneticGenesIntronsAtaxiaFutureMessenger RnaBaseSamplingPathogenicityPhenotypePathway InteractionsPlayMutantMouse ModelNeuronsProteinsCellsClinical ResearchFamilyFundingResearch PersonnelGenotype
Grant awards (27)
Genetic mechanism of conserved ancestral haplotype in SCA10$159,132
R01 · FY2023 · NS · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,098,761
U01 · FY2022 · NS · contact PI
Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (âREADISCAâ)$163,799
U01 · FY2022 · NS · contact PI
Genetic mechanism of conserved ancestral haplotype in SCA10$159,132
R01 · FY2022 · NS · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,220,506
U01 · FY2021 · NS · contact PI
Genetic mechanism of conserved ancestral haplotype in SCA10$159,132
R01 · FY2021 · NS · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,221,189
U01 · FY2020 · NS · contact PI
Genetic mechanism of conserved ancestral haplotype in SCA10$159,132
R01 · FY2020 · NS · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,183,360
U01 · FY2019 · NS · contact PI
The 1st SCA Global Conference$20,000
R13 · FY2019 · NS · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,260,926
U01 · FY2018 · NS · contact PI
RNA-Gain-of-Function Pathogenesis in SCA10$348,906
R01 · FY2017 · NS · contact PI
RNA-Gain-of-Function Pathogenesis in SCA10$348,906
R01 · FY2016 · NS · contact PI
RNA-Gain-of-Function Pathogenesis in SCA10$328,125
R01 · FY2015 · NS · contact PI
RNA-Gain-of-Function Pathogenesis in SCA10$323,942
R01 · FY2014 · NS · contact PI
RNA-Gain-of-Function Pathogenesis in SCA10$323,153
R01 · FY2013 · NS · contact PI
Clinical Research Consortium for Spinocerebellar Ataxias$500,000
RC1 · FY2010 · NS · contact PI
Clinical Research Consortium for Spinocerebellar Ataxias$500,000
RC1 · FY2009 · NS · contact PI
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10$329,897
R01 · FY2009 · NS · contact PI
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10$329,897
R01 · FY2008 · NS · contact PI
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10$329,897
R01 · FY2007 · NS · contact PI
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10$339,750
R01 · FY2006 · NS · contact PI
Spinocerebellar Ataxia Type 10$298,000
R01 · FY2004 · NS
Spinocerebellar Ataxia Type 10$298,000
R01 · FY2003 · NS
Spinocerebellar Ataxia Type 10$275,000
R01 · FY2002 · NS
Spinocerebellar Ataxia Type 10$16,405
R01 · FY2002 · NS
Spinocerebellar Ataxia Type 10$291,405
R01 · FY2001 · NS